Publications by authors named "David Maag"

Claim this Profile
C
CRISPR-Based Therapy for Hereditary Angioedema.
Danny M Cohn, Padmalal Gurugama, Markus Magerl, Constance H Katelaris, David Launay, David Maag

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRISPR-Cas9 In Vivo Gene Editing of for Hereditary Angioedema.
Hilary J Longhurst, Karen Lindsay, Remy S Petersen, Lauré M Fijen, Padmalal Gurugama, David Maag

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline / mutations and hormone receptor status from the phase-3 BROCADE3 trial.
Jean-Pierre Ayoub, Hans Wildiers, Michael Friedlander, Banu K Arun, Hyo S Han, David Maag

Ther Adv Med Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J Ansell, Mark Watson, David Maag

NPJ Breast Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, Jonathan Lehman, Daniel Morgensztern, David Maag

J Thorac Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Melissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, Aslaug Helland, Byoung Chul Cho, David Maag

J Thorac Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of Platinum-free Interval and Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g Advanced Breast Cancer (BROCADE3 Crossover).
Shannon L Puhalla, Véronique Diéras, Banu K Arun, Bella Kaufman, Hans Wildiers, David Maag

Clin Cancer Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
Banu K Arun, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, David Maag

Eur J Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
Hui K Gan, Sagun Parakh, Andrew B Lassman, Aidan Seow, Eddie Lau, David Maag

Neurooncol Adv· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
Otto Metzger Filho, Daniel G Stover, Sarah Asad, Peter J Ansell, Mark Watson, David Maag

JAMA Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Véronique Diéras, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, David Maag

Lancet Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
Mehra Golshan, Sibylle Loibl, Stephanie M Wong, Jens Bodo Houber, Joyce O'Shaughnessy, David Maag

JAMA Surg· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial.
Mehra Golshan, Stephanie M Wong, Sibylle Loibl, Jens Bodo Huober, Joyce O'Shaughnessy, David Maag

Eur J Surg Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Investigation of biaryl heterocycles as inhibitors of Wee1 kinase" [Bioorg. Med. Chem. Lett. 29 (2019) 1481-1486].
Anthony Mastracchio, Chunqiu Lai, Maricel Torrent, Kenneth Bromberg, Fritz G Buchanan, David Maag

Bioorg Med Chem Lett· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Biomarker Assays for : Implications for Precision Medicine in Patients with Glioblastoma.
Andrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, Minghao Song, Ekaterina Pestova, David Maag

Clin Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of biaryl heterocycles as inhibitors of Wee1 kinase.
Anthony Mastracchio, Chunqiu Lai, Maricel Torrent, Kenneth Bromberg, Fritz G Buchanan, David Maag

Bioorg Med Chem Lett· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Todd A Hopkins, William B Ainsworth, Paul A Ellis, Cherrie K Donawho, Enrico L DiGiammarino, David Maag

Mol Cancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Andrew B Lassman, Martin J van den Bent, Hui K Gan, David A Reardon, Priya Kumthekar, David Maag

Neuro Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, David Maag

Lancet Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Martin van den Bent, Hui K Gan, Andrew B Lassman, Priya Kumthekar, Ryan Merrell, David Maag

Cancer Chemother Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Michael L Curtin, H Robin Heyman, Richard F Clark, Bryan K Sorensen, George A Doherty, David Maag

Bioorg Med Chem Lett· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors.
Julie L Wilsbacher, Min Cheng, Dong Cheng, Samuel A J Trammell, Yan Shi, David Maag

Mol Cancer Ther· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
Yupeng He, Sujatha Selvaraju, Michael L Curtin, Clarissa G Jakob, Haizhong Zhu, David Maag

Nat Chem Biol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
Yupeng He, Sujatha Selvaraju, Michael L Curtin, Clarissa G Jakob, Haizhong Zhu, David Maag

Nat Chem Biol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Steven J Isakoff, Shannon Puhalla, Susan M Domchek, Michael Friedlander, Bella Kaufman, David Maag

Future Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis